Head-to-head · WeighScore
GoodRx vs RxSpan MD
By GLP-1 ScorecardUpdated
Score comparison
RxSpan MD has the higher recorded score — 84.3/100 to 69.6/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | GoodRx | RxSpan MD |
|---|---|---|
| WeighScore | 69.6/100 | 84.3/100 |
| Grade | C | B |
| Site position | #133 | #5 |
| Semaglutide | Not disclosed | Current compounded quote unconfirmed |
| Tirzepatide | $299/mo (brand Zepbound) | Current compounded quote unconfirmed |
| Coverage | All 50 states | Confirm treatment availability during intake |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #133 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
What to consider
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Site position #5 · B
Strengths
- Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
- Public terms describe independent healthcare providers
- Homepage describes messaging and care-team appointments
What to consider
- Homepage advertises compounded plans that the current catalog did not substantiate
- Current oral GLP-1 availability is unconfirmed
- Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
- Public terms do not establish unused prepaid-treatment refund amounts
Featured provider
RxSpan MD
RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.